CY1112102T1 - Υποκατεστημενες πυριμιδοδιαζεπινες χρησιμες ως αναστολεις plk1 - Google Patents

Υποκατεστημενες πυριμιδοδιαζεπινες χρησιμες ως αναστολεις plk1

Info

Publication number
CY1112102T1
CY1112102T1 CY20111101174T CY111101174T CY1112102T1 CY 1112102 T1 CY1112102 T1 CY 1112102T1 CY 20111101174 T CY20111101174 T CY 20111101174T CY 111101174 T CY111101174 T CY 111101174T CY 1112102 T1 CY1112102 T1 CY 1112102T1
Authority
CY
Cyprus
Prior art keywords
plk1
pyramidodiazepine
suspensions
substituted
formula
Prior art date
Application number
CY20111101174T
Other languages
Greek (el)
English (en)
Inventor
Jianping Cai
Shaoqing Chen
Xin-Jie Chu
Kang Le
Kin-Chun Thomas Luk
Peter Michael Wovkulich
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39415299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112102(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of CY1112102T1 publication Critical patent/CY1112102T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY20111101174T 2007-03-22 2011-11-30 Υποκατεστημενες πυριμιδοδιαζεπινες χρησιμες ως αναστολεις plk1 CY1112102T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91935807P 2007-03-22 2007-03-22
EP08717594A EP2139892B1 (en) 2007-03-22 2008-03-11 Substituted pyrimidodiazepines useful as plk1 inhibitors

Publications (1)

Publication Number Publication Date
CY1112102T1 true CY1112102T1 (el) 2015-11-04

Family

ID=39415299

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111101174T CY1112102T1 (el) 2007-03-22 2011-11-30 Υποκατεστημενες πυριμιδοδιαζεπινες χρησιμες ως αναστολεις plk1

Country Status (23)

Country Link
US (1) US7517873B2 (enExample)
EP (1) EP2139892B1 (enExample)
JP (1) JP5087640B2 (enExample)
KR (1) KR101157848B1 (enExample)
CN (2) CN102746175B (enExample)
AR (1) AR065794A1 (enExample)
AT (1) ATE524472T1 (enExample)
AU (1) AU2008228303B2 (enExample)
BR (1) BRPI0809088A2 (enExample)
CA (1) CA2680757A1 (enExample)
CL (1) CL2008000785A1 (enExample)
CY (1) CY1112102T1 (enExample)
DK (1) DK2139892T3 (enExample)
ES (1) ES2371832T3 (enExample)
HR (1) HRP20110807T1 (enExample)
IL (1) IL200617A (enExample)
MX (1) MX2009010034A (enExample)
PE (1) PE20120495A1 (enExample)
PL (1) PL2139892T3 (enExample)
PT (1) PT2139892E (enExample)
SI (1) SI2139892T1 (enExample)
TW (1) TWI363629B (enExample)
WO (1) WO2008113711A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461149B2 (en) 2007-08-15 2013-06-11 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinase inhibitors
CN103122001A (zh) 2007-09-25 2013-05-29 武田药品工业株式会社 Polo样激酶抑制剂
EP2610256B1 (en) * 2007-09-28 2016-04-27 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
US20090291938A1 (en) * 2007-11-19 2009-11-26 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
WO2009153197A1 (en) * 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Halo-substituted pyrimidodiazepines as plkl inhibitors
WO2010077613A1 (en) 2008-12-09 2010-07-08 Gilead Sciences, Inc. Modulators of toll-like receptors
EP2379559B1 (en) 2009-01-06 2017-10-25 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
GEAP202213376A (en) 2009-06-17 2022-02-25 Vertex Pharmaceuticals Incorporated Us Inhibitors of influenza viruses replication
EP2477987B1 (en) 2009-09-14 2018-01-10 Gilead Sciences, Inc. Modulators of toll-like receptors
CN103492381A (zh) 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
EP3670515B1 (en) 2013-03-15 2024-03-06 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
TWI652014B (zh) * 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
HUE052178T2 (hu) 2013-11-13 2021-04-28 Vertex Pharma Eljárások influenzavírus-replikáció inhibitorainak elõállítására
LT3068776T (lt) 2013-11-13 2019-08-12 Vertex Pharmaceuticals Incorporated Gripo virusų replikacijos inhibitoriai
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
EP4140485A1 (en) 2014-07-11 2023-03-01 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
EP3177626A4 (en) 2014-08-08 2017-12-27 Dana Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
JP6373490B2 (ja) 2014-09-16 2018-08-15 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体モジュレーターを調製する方法
EA201790369A1 (ru) 2014-09-16 2017-10-31 Джилид Сайэнс, Инк. Твердые формы модулятора толл-подобного рецептора
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
JP2018526424A (ja) 2015-09-11 2018-09-13 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用
US11306105B2 (en) 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
CR20180336A (es) 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
WO2017177092A1 (en) * 2016-04-07 2017-10-12 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating pi3k-mediated disorders
EP4034132B1 (en) * 2019-09-27 2026-02-25 Dana-Farber Cancer Institute, Inc. Erk5 degraders as therapeutics in cancer and inflammatory diseases
EP3911654A4 (en) * 2020-03-27 2022-05-11 Uppthera PLK1 SELECTIVE DEGRADATION-INDUCING COMPOUND
WO2022145989A1 (ko) * 2020-12-31 2022-07-07 (주) 업테라 선택적 plk1 억제제로서의 피리미도디아제핀 유도체
WO2023017442A1 (en) * 2021-08-10 2023-02-16 Uppthera, Inc. Novel plk1 degradation inducing compound
GB202313514D0 (en) 2023-09-05 2023-10-18 Cambridge Entpr Ltd Treatment of inflammatory diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2299434T3 (es) * 1999-09-17 2008-06-01 ABBOTT GMBH & CO. KG Inhibidores de kinasa utilizados como agentes terapeuticos.
EP1427730B1 (de) * 2001-09-04 2006-07-12 Boehringer Ingelheim Pharma GmbH & Co.KG Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
CA2652648C (en) * 2006-02-14 2016-10-25 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
TWI363629B (en) 2012-05-11
ES2371832T3 (es) 2012-01-10
IL200617A (en) 2014-02-27
AU2008228303A1 (en) 2008-09-25
HRP20110807T1 (hr) 2011-12-31
CA2680757A1 (en) 2008-09-25
WO2008113711A1 (en) 2008-09-25
BRPI0809088A2 (pt) 2014-09-09
US20080234255A1 (en) 2008-09-25
EP2139892B1 (en) 2011-09-14
PT2139892E (pt) 2011-11-21
CL2008000785A1 (es) 2009-03-27
MX2009010034A (es) 2009-10-12
PL2139892T3 (pl) 2012-03-30
CN101636399A (zh) 2010-01-27
CN102746175A (zh) 2012-10-24
AU2008228303B2 (en) 2012-04-19
PE20120495A1 (es) 2012-05-12
JP5087640B2 (ja) 2012-12-05
US7517873B2 (en) 2009-04-14
TW200843781A (en) 2008-11-16
JP2010521514A (ja) 2010-06-24
HK1139936A1 (en) 2010-09-30
CN102746175B (zh) 2014-01-15
ATE524472T1 (de) 2011-09-15
EP2139892A1 (en) 2010-01-06
SI2139892T1 (sl) 2011-12-30
KR101157848B1 (ko) 2012-07-11
CN101636399B (zh) 2012-04-18
AR065794A1 (es) 2009-07-01
DK2139892T3 (da) 2011-12-12
KR20090119913A (ko) 2009-11-20
IL200617A0 (en) 2010-05-17

Similar Documents

Publication Publication Date Title
CY1112102T1 (el) Υποκατεστημενες πυριμιδοδιαζεπινες χρησιμες ως αναστολεις plk1
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
CY1119218T1 (el) Αναστολεις διυδροπυριδοφθαλαζινονης της πολυμερασης της πολυαδενοσφωσφορικης ριβοζης (parp)
EA200900945A1 (ru) Новый способ синтеза агомелатина
DK2364308T3 (da) Pyrazinforbindelser som inhibitorer af Phosphodiesterase 10
CY1113131T1 (el) Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
CR20120295A (es) Triazolopiridinas
CY1112829T1 (el) Νεα μεθοδος συνθεσης για την αγομελατινη
UY29612A1 (es) Compuestos quimicos ii
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
CY1112705T1 (el) Συντηγμενες κυκλικες ενωσεις
MA32938B1 (fr) Composes organiques
CY1112595T1 (el) Αμιδοφαινοξυινδαζολια χρησιμα ως αναστολεις του c-met
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
CY1110010T1 (el) Πυριδιναμινοσουλφονυλ υποκατεστημενα βενζαμιδια ως αναστολεις κυτοχρωματος ρ450 3α4 (cyp3a4)
ATE400567T1 (de) Kinaseinhibitoren
CY1109234T1 (el) Αναστολεις κινασης
EA201101675A1 (ru) Спироэпоксиды как промежуточные продукты синтеза
CY1115094T1 (el) Νεα μεθοδος για την συνθεση (7-μεθοξυ-1-ναφθυλ) ακετονιτριλιου και εφαρμογη στην συνθεση αγομελατινης
EA200900943A1 (ru) Новый способ синтеза агомелатина
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
EA200900944A1 (ru) Новый способ получения кристаллической формы v агомелатина